跳至主要内容
临床试验/NCT07645443
NCT07645443招募中不适用

Mindfulness-based Group Therapy in Young Inpatients With Acute Early Psychosis (FEEL-GOOD)

Stephanie Mehl8 个研究点 分布在 1 个国家目标入组 252 人开始时间: 2026年5月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
252
试验地点
8
主要终点
Positive and Negative Symptom Scale Total Score (PANSS; Blinded assessment)

研究概览

简要总结

FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone. The intervention consists of one individual preparatory session and eight modularized group sessions delivered over four weeks involving four to eight participants at each session and including practice and homework tasks. Outcomes are assessed at baseline, 4 weeks post-intervention, and 6 months follow-up, with the primary outcome being observer-rated total psychopathology as measured with the assessed by the total score of the Positive and Negative Syndrome Scale (PANSS) post-treatment (4 weeks post baseline).

详细描述

After providing written informed consent, participants diagnoses will be confirmed with SCID-5-RV interview. The investigator will complete astandardized screening checklist to verify that all inclusion and exclusion criteria are (not) met prior to enrollment in the study. If patients they meet the required inclusion criteria and the exclusion criteria participants will complete baseline data assessment before randomization which will be performed adaptively fromwithin the data management system SecuTrial. Subjects will be randomized in a 1:1 allocation for each study site and will be balanced adaptively for gender and symptom severity as meas-ured by the PANSS total score (3 strata: mild with <54 points, moderate with 54-74 points, and high with >74 points). Participants will further complete two assessments at 4-week and6-month post-intervention. The final assessment for each participant (t3) constitutes the individual end of study participation. As participation is voluntary, participants may withdraw from the study prematurely at any time. Any withdrawal, and the reason for withdrawal will be documented. Reasons for withdrawal may include: 1) withdrawal of consent by participant defined as drop-out (without the need to provide justification), or 2) incorrect inclusion (e.g., subsequent determination of ineligibility).

The FEEL-GOOD trial aims to evaluate a mindfulness-based group therapy for young inpatients with acute early psychosis in addition to treatment as usual (TAU) in comparison to TAU at post-intervention (t2 after 4 weeks) regarding total psychopathology, positive and negative symptoms, and general psychopathology measured with the Positive and Negative Symp-tom Scale (PANSS), as well as acceptance of symptoms, mind- fulness-related and emotion regulation skills in inpatients with EP in comparison to the control group only receiving TAU. The rationale is that early psychosis is a critical treatment window, while current psychological interventions show limited efficacy and low adherence in younger patients; mindfulness-based interventions (MBI) may improve emotional awareness, acceptance, and emotion regulation.

Participants aged 16 to 35 years with early psychosis are recruited across eight German study sites (inpatient hospitals).

FEEL-GOOD is delivered by trained clinical psychologists or psychiatrists and consists of one individual preparatory session and eight modularized 50-minute group sessions over four weeks. Clinical psychologists or psychiatrists will conduct the intervention based on a detailed manual. It will follow the principals of MBI adapted for patients with psychosis. The patients will join the group therapy sessions (open-enrolling group) at any time and then participate at 8 consecutive sessions. Prior to the first group session, there will be an individual session with the study therapist, in which the participants will discuss and write down individual treatment goals related to mindfulness, emotional awareness and emotion regulation.

The core of the intervention will be to provide insights into and to practice the essential elements of mindfulness and emotion regulation: attention to the present moment, as well as non-judgmental awareness and acceptance, and application of emotional awareness and emotion regulation skills. The following modules will be provided: (1) Information on emotions (2 sessions); (2) How to use mindfulness to better cope with distressing emotions and symptoms. (2 sessions); (3) How to reduce vulnerability towards negative emotions (1 session) and (4) Regulation of specific distressing emotions (anger, guild and shame: 2 sessions) and (5) a last session on crisis planning. The intervention was developed in cooperation with Peer Coworkers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

This is a prospective randomized open blinded endpoint (PROBE) trial. Participants and care providers are aware of treatment allocation because of the nature of the intervention. Independent outcome assessors conducting clinician-rated measures are blinded to group assignment.

入排标准

年龄范围
16 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 16 to 35 years
  • •Clinical diagnosis of early psychosis, defined as first psychotic episode within the last 5 years as assessed with the Structural Clinical Interview for DSM-5 Research Version (SCID-5-RV)
  • •DSM-5 schizophrenia spectrum or other psychotic disorder confirmed with SCID-5-RV (DSM-5: 297.1, 298.8, 295.4, 295.9, 295.7, 298.8, 298.9) Currently receiving inpatient/day clinic treatment with a planned stay of at least 4 weeks
  • •Interested in and willing to participate in FEEL-GOOD and/or TAU.

排除标准

  • •Insufficient German language abilities
  • •Acute suicidality or acute threat to others

研究组 & 干预措施

FEEL-GOOD + TAU

Experimental

FEEL-GOOD + TAU. FEEL-GOOD consists of one individual preparatory session and eight modularized group sessions delivered over four weeks involving four to eight participants at each session and including practice and homework tasks. The core of the intervention will be to provide insights into and to practice the essential elements of mindfulness and emotion regulation: attention to the present moment, as well as non-judgmental awareness and acceptance, and application of emotional awareness and emotion regulation skills. The following modules will be provided: (1) Information on emotions (2 sessions); (2) How to use mindfulness to better cope with distressing emotions and symptoms. (2 sessions); (3) How to reduce vulnerability towards negative emotions (1 session) and (4) Regulation of specific distressing emotions (anger, guild and shame: 2 sessions) and (5) a last session on crisis planning. Patients additionally receive Treatment as Usual (TAU) as described below.

干预措施: FEEL GOOD (Behavioral)

TAU

Active Comparator

Participants receive treatment as usual (TAU), consisting of standard inpatient psychiatric care for early psychosis, including pharmacotherapy, supportive counselling, psychotherapeutic group interventions, occupational therapy, physiotherapy, and social work as clinically indicated.

干预措施: Treatment as Usual (TAU) (Other)

结局指标

主要结局

Positive and Negative Symptom Scale Total Score (PANSS; Blinded assessment)

时间窗: Baseline (t1), 4 weeks (t2); additional assessment at 6-months follow-up (t3)

The primary outcome is observer-rated (blinded) total psychopathology as measured by the total score of PANSS after 4 weeks (t2). PANSS is widely used and the gold standard for psychopathological outcomes in people with psychotic disorders. It integrates positive, negative, and general psychopathological symptoms.

次要结局

  • Ecological Momentary Assessment (EMA) (Self Report, putative mediator)(Starting at t1, EMA is assessed once a day during the intervention period including 7 days post t2-assessment at four weeks.)
  • Patient satisfaction questionnaire (ZUF) (Self Report, putative mediator)(4 weeks (t2), 6 months follow-up (t3))
  • Toronto Alexithymia Scale (TAS-26) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Positive and negative symptoms, general psychopathology as measured by PANSS Positive, Negative and General Psychopathology subscales (Blinded assessment)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Five-Facet Mindfulness Questionnaire (FFFM-D) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Rosenberg Self-Esteem Scale total score (RSES) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • World Health Organization Quality of Life - 100 item version (WHOQOL-BREF) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Cognitive Emotion Regulation Questionnaire (CERQ) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Emotion regulation skills (ERSQ) (Self Report, putative mediator)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Psychotic Symptom Rating Scales to assess delusions (PSYRATS-D) and hallucinations (PSYRATS-H) (Blinded assessment)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Depressive symptoms using the Calgary Depression Scale for Schizophrenia (CDSS) (Blinded asessment)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Role Functioning Scale (RFS) (Blinded assessment)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Global Assessment of Functioning (GAF), (Blinded assessment)(Baseline (t1), 4 weeks (t2), 6 months follow-up (t3))
  • Serious adverse events (SAEs) (Blinded Assessment)(Continuously during intervention and follow-up)

研究者

发起方
Stephanie Mehl
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Stephanie Mehl

Co-Principal Investigator

Berlin Institute of Health @ Charité

研究点 (8)

Loading locations...

相似试验